ArticleAmerican journal of translational research2026
Efficacy and safety analysis of double plasma molecular adsorption system plus plasma exchange for treating acute-on-chronic liver failure.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis retrospective study aimed to evaluate the efficacy and safety of the double plasma molecular adsorption system (DPMAS) plus plasma exchange (PE) in treating acute-on-chronic liver failure (ACLF).
methodsA total of 200 ACLF patients were enrolled and divided into two groups: the control group received PE therapy alone, while the observation group received DPMAS in addition to PE. Clinical data were collected from both groups, including treatment efficacy, safety, clinical indicators, symptom improvement, liver function, coagulation function, electrolytes, nutritional status, inflammatory markers, and short-term prognosis (assessed by the Model for End-Stage Liver Disease (MELD) score), and 12-week survival rate.
resultsCompared to the control group, the observation group showed notably higher total effective rates and greater symptom improvement at 4 weeks post-treatment. The fluctuation range of all coagulation indices after treatment was smaller in the observation group relative to the control group. Moreover, after treatment, the observation group showed a smaller number of PE treatments, less plasma volume used, and shorter length of hospital stay compared to the control group, as well as lower liver function indicator levels and MELD scores.
conclusionDPMAS combined with PE therapy demonstrates definite efficacy in ACLF treatment without increasing side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.